secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001799191-23-000012
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncology Institute CEO Brad Hively steps down, President Daniel Virnich promoted to CEO
--------------------------------------------------------------------------------

- Brad Hively resigns as CEO effective June 30, 2023; will become Vice Chairman of the Board.
- Daniel Virnich, current President, appointed CEO effective June 30, 2023.
- Hively's resignation not due to any disagreement; severance includes salary continuation, 50% of 2023 bonus, and RSU vesting through June 2024.
- Virnich joined TOI in 2020 as COO, promoted to President; previously at DaVita and TeamHealth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/0001799191-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/toi-20230611.htm
  HTML page:      https://secwatch.observer/filing/0001799191-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer